Patents by Inventor Daryl C. Drummond

Daryl C. Drummond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250064739
    Abstract: Aspects of the disclosure relate to various liposomal compositions of oxazolidinone compounds, and related methods of manufacturing and using the oxazolidinone liposome compositions. In some embodiments, the liposome compositions have improved storage stability with regard to component degradation.
    Type: Application
    Filed: December 22, 2022
    Publication date: February 27, 2025
    Applicant: Akagera Medicines, Inc.
    Inventors: Dmitri B. Kirpotin, Alexander Koshkaryev, Charles O. Noble, Daryl C. Drummond
  • Patent number: 12194034
    Abstract: The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a neutrophil-associated disease or condition in a subject in need thereof are also provided.
    Type: Grant
    Filed: March 27, 2024
    Date of Patent: January 14, 2025
    Assignee: IMMUNYX PHARMA LTD.
    Inventors: Daryl C. Drummond, Seth Jonah Salpeter
  • Publication number: 20250000796
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided. with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Application
    Filed: June 7, 2024
    Publication date: January 2, 2025
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • Publication number: 20240425495
    Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 26, 2024
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
  • Publication number: 20240425494
    Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 26, 2024
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
  • Patent number: 12145928
    Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: November 19, 2024
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
  • Patent number: 12116361
    Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: October 15, 2024
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
  • Publication number: 20240325525
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
    Type: Application
    Filed: May 24, 2024
    Publication date: October 3, 2024
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Publication number: 20240309291
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Publication number: 20240293390
    Abstract: The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a neutrophil-associated disease or condition in a subject in need thereof are also provided.
    Type: Application
    Filed: March 27, 2024
    Publication date: September 5, 2024
    Applicant: IMMUNYX PHARMA LTD.
    Inventors: Daryl C. DRUMMOND, Seth Jonah SALPETER
  • Patent number: 12077725
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Grant
    Filed: December 12, 2022
    Date of Patent: September 3, 2024
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Patent number: 12064479
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
    Type: Grant
    Filed: May 25, 2023
    Date of Patent: August 20, 2024
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Patent number: 12059497
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: August 13, 2024
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • Publication number: 20230416236
    Abstract: Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 1, 2023
    Publication date: December 28, 2023
    Inventors: Daryl C. DRUMMOND, Bolin GENG, Dmitri B. KIRPOTIN, Suresh K. TIPPARAJU, Alexander KOSHKARYEV, Ozan ALKAN
  • Patent number: 11844795
    Abstract: Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: December 19, 2023
    Inventors: Sarah F. Blanchette, Daryl C. Drummond, Jonathan Basil Fitzgerald, Victor Moyo
  • Publication number: 20230381303
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 30, 2023
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Publication number: 20230348447
    Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
    Type: Application
    Filed: December 13, 2022
    Publication date: November 2, 2023
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
  • Patent number: 11787781
    Abstract: Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: October 17, 2023
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
  • Publication number: 20230219941
    Abstract: Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 13, 2023
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Suresh K. Tipparaju, Charles O. Noble, Alexander Koshkaryev, Dmitri B. Kirpotin
  • Publication number: 20230181567
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 15, 2023
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Keelung Hong, Daryl C. Drummond, Dmitri B. Kirpotin